UNSPSC 51431901: Candesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C24H20N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8Q36MD2XX, chemically known as 1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as candesartan, which bears US NIH Compound Identifier 2541. Candesartan most often comes in base, celexetil, and hexetil forms.

UNSPSC 51431901 Candesartan, a Commodity code, represents a specific angiotensin II receptor antagonist pharmaceutical used in state and local government procurement primarily through emergency medical services, health department pharmacy benefit programs, and cooperative purchasing alliances rather than as a standalone line item. Recent activity shows that state and local governments are procuring candesartan and similar advanced life support and generic pharmaceuticals as part of broader medication supply contracts for emergency response, hospital formularies, and multi-state pharmacy benefit programs. The issuing-body mix includes city fire rescue departments (Tampa Fire Rescue), state health and human services agencies managing pharmacy benefits (Texas HHS Commission), and state-administered cooperative purchasing alliances serving multiple jurisdictions and government facilities (Minnesota Multistate Cooperative Purchasing Alliance). Governments buy candesartan embedded within larger pharmaceutical bundles that also include epinephrine, adenosine, labetalol, diltiazem, and other generic multi-source drugs and over-the-counter products, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers.

Recent activity concentrates in Texas and Minnesota, with secondary activity in Florida. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications in April 2026 with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00; the procurement required four specific medication line items with nine-month minimum expiration dating and ten-day delivery, carrying a 5 percent SLBE bid discount. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, seeking generic multi-source pharmaceutical manufacturers to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) for participating state and local government facilities in Minnesota and Oregon, with contracts effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The Texas HHS Commission issued RFI HHS0017013 in March 2026 as a preliminary market intelligence gathering on direct-to-manufacturer prescription programs rather than a binding procurement vehicle.